Greenleaf Trust’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.15M | Buy |
1,485
+13
| +0.9% | +$9.95K | 0.01% | 303 |
|
|
2025
Q4 | $1.14M | Buy |
1,472
+67
| +5% | +$45.5K | 0.01% | 300 |
|
|
2025
Q3 | $790K | Sell |
1,405
-43
| -3% | -$24.3K | 0.01% | 392 |
|
|
2025
Q2 | $760K | Sell |
1,448
-464
| -24% | -$259K | 0.01% | 393 |
|
|
2025
Q1 | $1.21M | Buy |
1,912
+3
| +0.2% | +$2.06K | 0.01% | 279 |
|
|
2024
Q4 | $1.36M | Sell |
1,909
-42
| -2% | -$35.2K | 0.01% | 267 |
|
|
2024
Q3 | $2.05M | Buy |
1,951
+3
| +0.2% | +$3.34K | 0.02% | 200 |
|
|
2024
Q2 | $2.05M | Buy |
1,948
+48
| +3% | +$46.5K | 0.02% | 178 |
|
|
2024
Q1 | $1.83M | Sell |
1,900
-3
| -0.2% | -$2.85K | 0.02% | 194 |
|
|
2023
Q4 | $1.67M | Buy |
1,903
+63
| +3% | +$51.9K | 0.02% | 204 |
|
|
2023
Q3 | $1.51M | Sell |
1,840
-32
| -2% | -$25.1K | 0.02% | 202 |
|
|
2023
Q2 | $1.35M | Sell |
1,872
-157
| -8% | -$121K | 0.01% | 222 |
|
|
2023
Q1 | $1.67M | Buy |
2,029
+86
| +4% | +$64.9K | 0.02% | 189 |
|
|
2022
Q4 | $1.4M | Buy |
1,943
+174
| +10% | +$128K | 0.02% | 210 |
|
|
2022
Q3 | $1.22M | Buy |
1,769
+306
| +21% | +$193K | 0.02% | 207 |
|
|
2022
Q2 | $865K | Sell |
1,463
-180
| -11% | -$117K | 0.01% | 259 |
|
|
2022
Q1 | $1.15M | Buy |
1,643
+195
| +13% | +$123K | 0.01% | 223 |
|
|
2021
Q4 | $914K | Buy |
1,448
+32
| +2% | +$19.7K | 0.01% | 267 |
|
|
2021
Q3 | $857K | Buy |
1,416
+27
| +2% | +$16.8K | 0.01% | 253 |
|
|
2021
Q2 | $776K | Buy |
1,389
+82
| +6% | +$41.5K | 0.01% | 283 |
|
|
2021
Q1 | $618K | Buy |
1,307
+267
| +26% | +$130K | 0.01% | 322 |
|
|
2020
Q4 | $502K | Sell |
1,040
-144
| -12% | -$77.7K | 0.01% | 339 |
|
|
2020
Q3 | $663K | Buy |
1,184
+20
| +2% | +$12.1K | 0.01% | 232 |
|
|
2020
Q2 | $726K | Buy |
1,164
+273
| +31% | +$155K | 0.01% | 204 |
|
|
2020
Q1 | $435K | Buy |
891
+277
| +45% | +$114K | 0.01% | 270 |
|
|
2019
Q4 | $231K | Sell |
614
-125
| -17% | -$42.1K | ﹤0.01% | 478 |
|
|
2019
Q3 | $205K | Buy |
+739
| New | +$219K | ﹤0.01% | 520 |
|
|
2019
Q2 | – | Sell |
-992
| Closed | -$407K | – | 558 |
|
|
2019
Q1 | $407K | Buy |
992
+97
| +11% | +$39.9K | 0.01% | 306 |
|
|
2018
Q4 | $334K | Buy |
895
+80
| +10% | +$29.3K | 0.01% | 340 |
|
|
2018
Q3 | $329K | Buy |
815
+145
| +22% | +$55.2K | 0.01% | 370 |
|
|
2018
Q2 | $231K | Buy |
+670
| New | +$210K | ﹤0.01% | 441 |
|
|
2018
Q1 | – | Sell |
-43
| Closed | -$16K | – | 637 |
|
|
2017
Q4 | $16K | Hold |
43
| – | – | ﹤0.01% | 627 |
|
|
2017
Q3 | $19K | Buy |
+43
| New | +$20.5K | ﹤0.01% | 582 |
|
Other funds holding REGN
VCM
N
Greenleaf Trust's REGN Position: Q1 2026 in Review
Greenleaf Trust increased its Regeneron Pharmaceuticals (REGN) stake by 0.88% in Q1 2026, buying an estimated $9.95K and bringing the position to 1,485 shares worth $1.15M. The position accounts for 0.01% of the portfolio, ranked #303.
Greenleaf Trust first reported a position in REGN in Q3 2017 and has held it in 33 quarters since. The position peaked at $2.05M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Greenleaf Trust held 1,485 shares of Regeneron Pharmaceuticals worth $1.15M as of Q1 2026.
- Greenleaf Trust bought 13 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $9.95K.
- Regeneron Pharmaceuticals made up 0.01% of Greenleaf Trust's portfolio in Q1 2026, its #303 holding.
- Greenleaf Trust first reported a position in Regeneron Pharmaceuticals in Q3 2017 and has held it in 33 quarters since.
- Greenleaf Trust's Regeneron Pharmaceuticals position peaked at $2.05M in Q3 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Greenleaf Trust's 13F filing for Q1 2026, filed 27 Apr 2026.